Functional assay.
Dose-escalation effects of a combination of dovitinib (mM) and TRAIL and tigatuzumab on apoptosis in four HCC cells. Cells were exposed to dovitinib and/or TRAIL or tigatuzumab at the indicated doses for 24 h. Apoptotic cells (sub-G1) were analyzed by flowcytometry.
Western Blotting.
Left: Overexpression of YIPF2 in H1299 cells in the presence or absence of cycloheximide (CHX) for the indicated times (0, 4, 8 and 12 h). Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B and ACTB. Right: The band intensity of TNFRSF10B was quantified by ImageJ software and plotted.
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody. Learn More
Citations
Have you cited CABT-CS378 in a publication? Let us know and earn a reward for your research.
Functional assay.
Dose-escalation effects of a combination of dovitinib (mM) and TRAIL and tigatuzumab on apoptosis in four HCC cells. Cells were exposed to dovitinib and/or TRAIL or tigatuzumab at the indicated doses for 24 h. Apoptotic cells (sub-G1) were analyzed by flowcytometry.
Western Blotting.
Left: Overexpression of YIPF2 in H1299 cells in the presence or absence of cycloheximide (CHX) for the indicated times (0, 4, 8 and 12 h). Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B and ACTB. Right: The band intensity of TNFRSF10B was quantified by ImageJ software and plotted.
My Review for Anti-Human TNFRSF10B (tigatuzumab biosimilar) Monoclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.